Every 424B that Pulse Biosciences, Inc (PLSE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PLSE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLSE filings page.
Pulse Biosciences, Inc. (PLSE) filed a prospectus supplement for a new at-the-market equity program, allowing sales of up to $85,000,000 of common stock from time to time through Mizuho Securities USA LLC as sales agent under its $200,000,000 shelf registration. The company expects to complete its prior August 2026 ATM program before using this new facility. Shares outstanding were 70,799,962 as of June 30, 2026, and would be up to 72,367,938 if 1,567,976 shares were sold at $54.21 per share.
Net proceeds, if any, are intended for general corporate purposes, primarily to fund clinical evaluations and IDE studies of the nPulse Cardiac Catheter and nPulse Cardiac Clamp in the U.S. and Europe, regulatory submissions, and further development and early commercialization of the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and other applications. The filing highlights that investors may experience substantial dilution: at an assumed price of $54.21, as-adjusted net tangible book value would be $2.47 per share, implying immediate dilution of $51.74 to new investors, while existing holders would see a $1.11 per-share increase in net tangible book value.
Pulse Biosciences, Inc. is establishing an at-the-market equity program to sell up to $75,000,000 of common stock from time to time through Mizuho Securities USA LLC under an existing $200,000,000 shelf registration. Mizuho will act as sales agent on commercially reasonable efforts terms and receive up to 3% of gross proceeds as commissions.
The company had 70,799,962 shares outstanding as of June 30, 2026; an illustrative sale of 1,978,891 shares at $37.90 per share would raise approximately $75 million and increase shares outstanding to 72,778,853. Historical net tangible book value was $96.5 million, or $1.36 per share, and would rise to $169.0 million, or $2.32 per share on an illustrative basis, implying dilution of $35.58 per share at a $37.90 offering price.
Net proceeds are intended for general corporate purposes, including clinical evaluations and IDE studies for the nPulse Cardiac Catheter and nPulse Cardiac Clamp in the United States and Europe, regulatory submissions, and further development and commercialization of the Vybrance Percutaneous Electrode System and other NPS-based products.
Pulse Biosciences, Inc. entered into a sales agreement with TD Securities (USA) LLC to sell up to $59,976,196 of its common stock in an at-the-market offering under a shelf registration.
The supplement states the offering may be made from time to time through TD Cowen, that TD Cowen will act as sales agent for up to $59,976,196, and that compensation to TD Cowen may be up to 3% of gross proceeds. Shares outstanding used for illustrative dilution are 67,839,689 as of December 31, 2025.